Vincenzo De Tata

Palmitate activates autophagy in INS-1E β-cells and in isolated rat and human pancreatic islets.

We have investigated the in vitro effects of increased levels of glucose and free fatty acids on autophagy activation in pancreatic beta cells. INS-1E cells and isolated rat and human pancreatic islets were incubated for various times (from 2 to 24 h) at different concentrations of glucose and/or palmitic acid. Then, cell survival was evaluated and autophagy activation was explored by using various biochemical and morphological techniques. In INS-1E cells as well as in rat and human islets, 0.5 and 1.0 mM palmitate markedly increased autophagic vacuole formation, whereas high glucose was ineffective alone and caused little additional change when combined with palmitate. Furthermore, LC3-II immunofluorescence co-localized with that of cathepsin D, a lysosomal marker, showing that the autophagic flux was not hampered in PA-treated cells. These effects were maintained up to 18-24 h incubation and were associated with a significant decline of cell survival correlated with both palmitate concentration and incubation time. Ultrastructural analysis showed that autophagy activation, as evidenced by the occurrence of many autophagic vacuoles in the cytoplasm of beta cells, was associated with a diffuse and remarkable swelling of the endoplasmic reticulum. Our results indicate that among the metabolic alterations typically associated with type 2 diabetes, high free fatty acids levels could play a role in the activation of autophagy in beta cells, through a mechanism that might involve the induction of endoplasmic reticulum stress.

Age-Related Impairment of Pancreatic Beta-Cell Function: Pathophysiological and Cellular Mechanisms

The incidence of type 2 diabetes significantly increase with age. The relevance of this association is dramatically magnified by the concomitant global aging of the population, but the underlying mechanisms remain to be fully elucidated. Here some recent advances in this field are reviewed, at the level of both the pathophysiology of glucose homeostasis and the cellular senescence of pancreatic islets. Overall, recent results highlight the crucial role of beta-cell dysfunction in the age-related impairment of pancreatic endocrine function and delineate the possibility of new original therapeutic interventions .

Membrane gamma-glutamyl transferase activity promotes iron-dependent oxidative DNA damage in melanoma cells.

A number of recent observations have suggested a potential role for membrane-bound gamma-glutamyltransferase (GGT) in tumor progression and appearance of more aggressive and resistant phenotypes, through redox interactions leading to production of reactive oxygen species. The present study was aimed to evaluate whether such pro-oxidant activity of GGT can promote oxidative DNA damage, thus contributing to cancer genomic instability. Human GGT-transfected melanoma cells were studied, and DNA damage was measured by using the alkaline comet assay. Our results indicate that higher levels of GGT activity are associated with higher levels of background DNA damage and oxidized bases. This association cannot be explained by differences in cell cycle distribution or apoptotic rates. GGT-over-expressing cells also presented with a markedly higher glucose uptake, a phenomenon potentially leading to higher metabolic rate and oxidative DNA damage. Anyway, when GGT-over-expressing cells were incubated in the presence of GGT substrates and a source of catalytic iron, increased levels of DNA damage and oxidized bases were observed, an effect completely prevented in the presence of GGT inhibitors or various antioxidants.The findings reported indicate that GGT activity is able to promote iron-dependent DNA oxidative damage, thus potentially representing an important mechanism in initiation/progression of neoplastic transformation.

Oral tungstate treatment improves only transiently alteration of glucose metabolism in a new rat model of type 2 diabetes.

It has been shown that tungstate is an effective hypoglycemic agent in several animal models of diabetes. In this study, we examined the effectiveness of oral tungstate treatment in a new experimental diabetic syndrome, induced by streptozotocin (STZ) and nicotinamide in adult rats, that shares several features with human type 2 diabetes. Sodium tungstate was administered in the drinking water (2 mg/mL) of control and diabetic rats for 15, 30, 60, and 90 d. Glucose metabolism was explored in vivo by intravenous glucose tolerance test. Insulin secretion and action were assessed in vitro in the isolated perfused pancreas and isolated adipocytes, respectively. Two weeks of tungstate treatment did not modify the moderate hypergly cemia of diabetic rats but reduced their intolerance to glucose, owing to an enhancement of postloading insulin secretion. However, this effect was transient, since it declined after 30 d and vanished after 60 and 90 d of tungstate administration, whereas a trend toward a reduction in basal hyperglycemia was observed on prolonged treatment. Oral tungstate was unable to modify glucose-stimulated insulin secretion in the isolated perfused pancreas, as well as muscle glycogen levels, hepatic glucose metabolism, and insulin-stimulated lipogenesis in isolated adipocytes. Nevertheless, the decreased insulin content of pancreatic islets of diabetic rats was partially restored on prolonged tungstate treatment. In conclusion, in the STZ-nicotinamide model of diabetes, tungstate was unable to permanently correct the alterations in glucose metabolism, despite some indirect evidence of a trophic effect on β-cells. The ineffectiveness of tungstate could be related to the absence, in this diabetic syndrome, of relevant metabolic alterations in the liver, which thus appear to constitute the major target of tungstate action.

Mast cells infiltrate pancreatic islets in human type 1 diabetes

Aims/hypothesisBeta cell destruction in human type 1 diabetes occurs through the interplay of genetic and environmental factors, and is mediated by immune cell infiltration of pancreatic islets. In this study, we explored the role of mast cells as an additional agent in the pathogenesis of type 1 diabetes insulitis.MethodsPancreatic tissue from donors without diabetes and with type 1 and 2 diabetes was studied using different microscopy techniques to identify islet-infiltrating cells. The direct effects of histamine exposure on isolated human islets and INS-1E cells were assessed using cell-survival studies and molecular mechanisms.ResultsA larger number of mast cells were found to infiltrate pancreatic islets in samples from donors with type 1 diabetes, compared with those from donors without diabetes or with type 2 diabetes. Evidence of mast cell degranulation was observed, and the extent of the infiltration correlated with beta cell damage. Histamine, an amine that is found at high levels in mast cells, directly contributed to beta cell death in isolated human islets and INS-1E cells via a caspase-independent pathway.Conclusions/interpretationThese findings suggest that mast cells might be responsible, at least in part, for immune-mediated beta cell alterations in human type 1 diabetes. If this is the case, inhibition of mast cell activation and degranulation might act to protect beta cells in individuals with type 1 diabetes.

Association of Dioxin and Other Persistent Organic Pollutants (POPs) with Diabetes: Epidemiological Evidence and New Mechanisms of Beta Cell Dysfunction

The worldwide explosion of the rates of diabetes and other metabolic diseases in the last few decades cannot be fully explained only by changes in the prevalence of classical lifestyle-related risk factors, such as physical inactivity and poor diet. For this reason, it has been recently proposed that other “nontraditional” risk factors could contribute to the diabetes epidemics. In particular, an increasing number of reports indicate that chronic exposure to and accumulation of a low concentration of environmental pollutants (especially the so-called persistent organic pollutants (POPs)) within the body might be associated with diabetogenesis. In this review, the epidemiological evidence suggesting a relationship between dioxin and other POPs exposure and diabetes incidence will be summarized, and some recent developments on the possible underlying mechanisms, with particular reference to dioxin, will be presented and discussed.

Dehydroascorbate protection against dioxin-induced toxicity in the β-cell line INS-1E.

Oxidative stress has been proposed as a mechanism of the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD). The aim of this research was to evaluate the protective effects of increased intracellular ascorbate levels against TCDD acute toxicity in the insulin-secreting beta-cell line INS-1E. Ascorbate is considered a potent antioxidant, but its therapeutic efficacy is greatly limited by its slow achievement of high intracellular levels. This might be circumvented by administration of dehydroascorbate (DHA), which is transported at a much higher rate and undergoes rapid intracellular reduction to ascorbate. Indeed, 30 min incubation of INS-1E cells with various concentrations of DHA caused a remarkable, dose-related increase of the intracellular ascorbate levels. INS-1E cells preincubated with 0.5 and 1.0mM DHA showed a greater viability than control cells after 1h exposition to cytotoxic TCDD concentrations. In our experimental conditions, TCDD surprisingly failed to increase ROS production in INS-1E cells, but induced a dose-related mitochondrial depolarisation which was significantly improved by DHA preincubation. Furthermore, DHA preincubation completely prevented the low dose TCDD-induced inhibition of glucose-stimulated insulin secretion. Thus, our results suggest that DHA preincubation protects INS-1E cells against TCDD acute toxicity by partially preserving mitochondrial function.

Direct effects of rosuvastatin on pancreatic human beta cells.

The 3-hydroxy-methylglutaryl coenzyme A inhibitors statins are largely used for primary and secondary prevention of atherosclerotic cardiovascular disease in both non-diabetic and diabetic patients [1, 2]. However, recent work has suggested that statin therapy may be associated with increased risk of new onset diabetes and deterioration of glycemic control. The concern was initially raised in 2008, when increased incidence of diabetes among patients taking rosuvastatin in the JUPITER study was reported [3]. A successive meta-analysis of randomized placebo-controlled and standard care–controlled trials (19,140 subjects of whom 4,278 developed diabetes) demonstrated a 9 % increased risk of incident diabetes in statin-treated individuals [4]. The benefits of statin treatment largely exceed the diabetes hazard [5–7]; nevertheless, it is important to investigate the mechanisms through which these molecules might affect glucose homeostasis. In this study, we have assessed the direct action of rosuvastatin on isolated human islets. Insulin secretion, beta cell survival, ultrastructure and gene expression studies were performed.

The use of multilayer nano-encapsulation for the immunoprotection of isolated human islets: in vitro and in vivo studies.

1-OR Similar 3-Year-Mortality in Patients with STEMI and NSTEMI for Known as well as for Newly Diagnosed Diabetes—Results of the SWEETHEART Registry ANSELM K. GITT, PETER BRAMLAGE, STEFFEN SCHNEIDER, RALF ZAHN, DIETHELM TSCHÖPE, SWEETHEART-STUDY-GROUP, Ludwigshafen, Germany, Mahlow, Germany, Bad Oeynhausen, Germany Joint ESC/EASD guidelines recommend testing for diabetes (DM) using oral glucose tolerance test (OGTT) in patients with CAD. SWEETHEART enrolled 2,767 consecutive patients (pts) with STEMI or NSTEMI to identify newly diagnosed DM (new DM) and to document outcome. In pts without DM, OGTT was performed at day 4 after the MI. We examined the impact of known and new DM on 3-year-outcome. OGTT detected 16.0%.new DM in STEMI and 17.8% in NSTEMI. Pts with new DM were younger and suffered from less concomitant diseases. 3-year-mortality rates were high, both for known and for new DM, without differences between STEMI and NSTEMI. OGTT after acute MI identifi ed new DM in 16.0% of STEMI and 17.8% of NSTEMI-pts. For known and new DM, 3-year-mortality was similar for STEMI and NSTEMI.

The immunoproteasome is induced by cytokines and regulates apoptosis in human islets

In addition to degrading misfolded and damaged proteins, the proteasome regulates the fate of cells in response to stress. The role of the proteasome in pro-inflammatory cytokine-induced human beta-cell apoptosis is unknown. Using INS-1, INS-1E and human islets exposed to combinations of IFNγ, IL-1β and TNFα with or without addition of small molecules, we assessed the role of the immunoproteasome in pancreatic beta-cell demise. Here, we show that cytokines induce the expression and activity of the immuno-proteasome in INS-1E cells and human islets. Cytokine-induced expression of immuno-proteasome subunits, but not activity, depended upon histone deacetylase 3 activation. Inhibition of JAK1/STAT1 signaling did not affect proteasomal activity. Inhibition of the immuno-proteasome subunit PSMB8 aggravated cytokine-induced human beta-cell apoptosis while reducing intracellular levels of oxidized proteins in INS-1 cells. While cytokines increased total cellular NFκB subunit P50 and P52 levels and reduced the cytosolic NFκB subunit P65 and IκB levels, these effects were unaffected by PSMB8 inhibition. We conclude that beta cells upregulate immuno-proteasome expression and activity in response to IFNγ, likely as a protective response to confine inflammatory signaling.